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Fat malabsorption induced by gastrointestinal lipase inhibitor
leads to an increase in urinary oxalate excretion.
Background. Unabsorbed fat and bile acids may react with
calcium in the intestinal lumen, limiting the amount of free cal-
cium binding with oxalate and thereby raising intestinal oxalate
absorption leading to hyperoxaluria. The aim of the present
study was to determine whether orlistat (Xenical), a gastroin-
testinal lipase inhibitor, might increase urinary oxalate in an
experimental rat model.
Methods. Thirty-nine male adult Wistar rats were fed a stan-
dard diet alone (controls) or supplemented with either 2%
sodium oxalate (NaOx) or 3.2 mL of soy oil, or with both (NaOx
+ soy oil) for 4 weeks (diet period). Orlistat (16 mg/day) was
added to the diet from the 5th to the 8th week (diet + orlis-
tat period). Urinary oxalate (uOx), calcium (uCa), magnesium
(uMg), and citrate (uCit) were determined and the ion-activity
product of calcium oxalate [AP (CaOx) indexrat] was estimated.
Results. Compared to baseline uOx significantly increased af-
ter diet + orlistat in controls (0.64 ± 0.1 mg/24 hours vs. 0.56 ±
0.1 mg/24 hours), soy oil (0.80 ± 0.3 mg/24 hours vs. 0.49 ±
0.2 mg/24 hours), and NaOx (2.48 ± 0.8 mg/24 hours vs. 0.57
± 0.2 mg/24 hours), but the most marked increase occurred in
NaOx + soy oil (3.87 ± 0.7 mg/24 hours vs. 0.47 ± 0.1 mg/24
hours). All groups except controls presented a significant re-
duction in uCa and uMg. Orlistat induced a significant increase
in AP (CaOx) indexrat compared, respectively, to baseline and
to the diet period in NaOx (4.52 ± 2.34 mg/24 hours vs. 0.94 ±
0.86 and 1.53 ± 0.93 mg/24 hours) and NaOx + soy oil (6.49 ±
4.03 mg/24 hours vs. 0.54 ± 0.17 and 1.76 ± 1.32 mg/24 hours).
Conclusion. These data suggest that the use of lipase in-
hibitors, especially under a diet rich in oxalate alone or asso-
ciated with fat, leads to a significant and marked increase in
urinary oxalate and a slight reduction in uCa and uMg that,
taken together, resulted in an increase in AP (CaOx) indexrat,
elevating the risk of stone formation.
Hyperoxaluria is one of the major risk factors for cal-
cium oxalate stone formation due to urinary calcium ox-
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alate (CaOx) supersaturation, since the latter is directly
correlated with urinary oxalate (uOx) concentration
[1–3].
In healthy individuals, most of the uOx derives from
hepatic synthesis and enzymatic conversion of ascorbic
acid, with between 10% and 50% being provided by di-
etary intake [4, 5].
Clinically, hyperoxaluria can be due to an enzymatic
disturbance in oxalate biosynthesis (primary hyperox-
aluria type I and II, or pyridoxine deficiency), but pri-
mary hyperoxaluria type I, the prevailing type, is a very
rare autosomal-recessive disorder [6, 7]. Secondary hy-
peroxaluria is due to either increased availability of sub-
strate (ascorbic acid, ethylene glycol, methoxyflurane) [8]
or to intestinal hyperabsorption of oxalate caused by a
high oxalate diet, enteric hyperoxaluria, or an imbalance
between intraluminal calcium and oxalate as in a low-
calcium diet [9–13].
Enteric hyperoxaluria induced by fat and bile salt mal-
absorption is the hallmark of hyperoxaluria due to in-
testinal hyperabsorption of oxalate. The gastrointestinal
diseases that have been associated with this entity are
those characterized by an absence or nonfunction of the
small bowel (enteritis, small bowel resection, or bypass
surgery) and those causing defective absorption of fat
or bile acids (chronic pancreatitis, biliary cirrhosis, blind
loop syndrome, and other diseases) [14–17]. Unabsorbed
bile acids and fatty acids may react with calcium in the
intestinal lumen, forming “soaps” that limit the amount
of free calcium binding with oxalate, with a consequent
increase in intestinal oxalate absorption leading to hyper-
oxaluria [14, 18–23]. It has also been shown that bile acids
may directly increase the colonic permeability to oxalate
[24, 25].
Orlistat, a chemically synthesized derivative of the nat-
ural product lipstatin originally isolated from Strepto-
myces toxytricini, is a specific inhibitor of pancreatic and
gastric lipases [26] used to reduce body weight in humans
[27, 28].
We hypothesized that fat malabsorption induced by
a gastrointestinal lipase inhibitor and the excess of bile
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salts could complex with calcium and reduce the forma-
tion of CaOx insoluble compounds in the intestinal lu-




Thirty-nine male Wistar rats weighing 230 to 320 g,
kept in individual cages for 8 weeks, were divided into
four groups according to the diet administered: stan-
dard chow containing 1.02% calcium, 0.80% phospho-
rus, 0.35% magnesium, 1.07% potassium, 0.27% sodium,
and 5.2% fat/g (controls, N = 10), or supplemented with
sodium oxalate (NaOx) added at 2.0% concentration
(NaOx group, N = 10), or with 3.2 mL soy oil to increase
the amount of lipids in the diet (soy oil group, N = 9),
or supplemented with both (NaOx + soy oil group, N =
10). The supplements were mixed with the powdered diet.
Rats were given access to 20g/day of the ground diet dur-
ing the whole period of the experiment except for the
day in which feces and urine were collected (see explana-
tion below). From the 5th week to the end of the experi-
ment, all groups received a daily single oral dose of 16 mg
(800 mg/kg of chow) of orlistat (Xenical) [29, 30], which
was mixed with the diet. Rats that ate less than 16 g of
food were not included in the study.
Feces for the measurement of the percentage of fat,
and 24-hour urine samples for the measurement of uri-
nary volume, uOx, calcium (uCa), magnesium (uMg),
citrate (uCit), sodium (uNa), potassium (uK), creatinine
(uCreat), and urinary pH (upH), were obtained at base-
line and after 4 weeks to assess the effect of diet alone
(diet period), and after 8 weeks to assess the effect of diet
plus orlistat (diet + orlistat period). Forty-eight hours
before feces and urine collection, the rats were placed
in metabolic cages for adaptation. On the collection day,
the NaOx supplements were given by gavage to prevent
contamination of urine samples with chow containing ox-
alate. The experimental protocol was approved by the
Ethics Committee for Animal Experiments of Universi-
dade Federal de Sa˜o Paulo.
Urinary parameters
The urine samples were divided into 2 aliquots: one
containing 6 N HCl (20 mL/L) for measurements of
uOx, uCa, uCit, and uMg, and the other placed in a
dry container for upH, uNa, uK, and uCreat determi-
nation. Calcium was determined by atomic absorption
spectrophotometry (Perkin Elmer Atomic Spectropho-
tometer 290-B) (Norwalk, CN, USA); oxalate by an
enzymatic method [31] using the Sigma Oxalate Diag-
nostic Kit (Sigma Chemical Co., St Louis, MO, USA),
and sodium and potassium by flame photometry (B-
462–Micronal). Creatinine was determined by Jaffe’s
method [32], magnesium was determined by combination
with calmagite (Labtest Diagnostics Kit) (Minas Gerais,
Brazil) and citrate by an enzymatic assay using citrate
lyase [33]. Urinary pH was determined with a pH univer-
sal tape (pHydrion Paper Dispenser) (Micro Essential,
NY, USA).
Feces
Percent fecal fat was quantified by the steatocrit tech-
nique [34–37], which is based on a calculation that con-
siders the liquid part [fatty layer (F)] and solid part [solid
layer (S)] in isolated excrement samples, according to the
formula: steatocrit (percent of fat in feces) = [F ÷ (S + F)]
× 100. The steatocrit measurement was performed twice
in each fecal sample, and the mean of two measurements
was then considered.
Ion-activity product
The ion activity product of CaOx [AP (CaOx) indexrat]
was calculated based on the urinary values of uOx, uCa,
uMg, uCit, and volume according to the following for-
mula: [(4067 × Ca0.93 × Ox0.96) × (Mg−0.55 × (Cit +
0.015)−0.60 × V−0.99)], derived from AP (CaOx) Tiselius
Index, originally used for human urine [38]. The adapta-
tion for rat urine has been based on average urine compo-
sition obtained from literature [39] and our own analytical
data. The relative effect of each urine variable was as-
sessed by means of an iterative computerized approxi-
mation with the Equil 2 program [40]. There was a good
correlation (r = 0.89) between AP (CaOx) indexrat cal-
culated by our recently published adapted formula [41]
and AP (CaOx) as derived from Equil 2.
Histologic analysis
At the end of the study, the kidney of two rats from each
group was removed under ether anesthesia, cut longitudi-
nally and fixed with 10% formaldehyde for hematoxylin
and eosin staining. Crystal deposition in renal tissue was
searched under polarized light microscopy. A case of a
kidney transplanted patient who developed acute tubu-
lar necrosis with heavy CaOx tubular deposition was used
as a positive control.
Statistical analysis
With the exception of citrate and magnesium, none of
the parameters presented a normal curve distribution, ac-
cording to the Kolmogorov-Smirnov test. Therefore, only
nonparametric tests were employed. The Friedman’s test
was used to compare the results between baseline, diet,
and diet + orlistat within each group, and the Kruskal-
Wallis, complemented by Dunn’s test was used to com-
pare the results between groups in the same period. The
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Table 1. Urinary parameters mean values at baseline, after diet and diet + orlistat periods
Groups
Sodium oxalate Sodium oxalate
Urinary parameters Control Soy oil (NaOx) (NaOx) + soy oil
Volume ml
Baseline 11.1 ± 5.0d 17.4 ± 2.9 10.5 ± 3.5d 11.3 ± 1.2d
Diet 11.7 ± 4.9 6.8 ± 1.6a,c 5.4 ± 1.7a,c 5.7 ± 2.2a,c
Diet + orlistat 16.0 ± 5.5 9.1 ± 3.3a,c 5.5 ± 1.5a,c,d 6.5 ± 2.3a,c,d
Oxalate mg/24 hours
Baseline 0.56 ± 0.1 0.49 ± 0.2 0.57 ± 0.2 0.47 ± 0.1
Diet 0.49 ± 0.1 0.87 ± 0.4a,c 1.60 ± 1.3a,c 3.13 ± 0.9a,c,d,e
Diet + orlistat 0.64 ± 0.1a,b 0.80 ± 0.3a,c 2.48 ± 0.8a,b,c,d 3.87 ± 0.7a,c,d,e
Calcium mg/24 hours
Baseline 0.26 ± 0.1d,e 0.49 ± 0.0 0.39 ± 0.1 0.38 ± 0.0c
Diet 0.31 ± 0.1 0.31 ± 0.0a 0.08 ± 0.0a,c,d 0.04 ± 0.0a,c,d,e
Diet + orlistat 0.45 ± 0.1 0.38 ± 0.1a 0.08 ± 0.0a,c,d 0.16 ± 0.0a,c,d
Citrate mg/24 hours
Baseline 10.5 ± 9.9 14.8 ± 4.2 14.4 ± 8.8 14.1 ± 5.3
Diet 13.8 ± 4.0 8.8 ± 2.3a 9.1 ± 7.2 12.7 ± 9.6
Diet + orlistat 17.0 ± 2.9 12.1 ± 4.7c 6.2 ± 5.5a,c,d 10.3 ± 6.3c
Sodium mEq/L
Baseline 0.7 ± 0.3 0.9 ± 0.2 0.6 ± 0.1 0.6 ± 0.1
Diet 0.4 ± 0.1 0.8 ± 0.2c 2.5 ± 1.0a,c,d 2.9 ± 1.7a,c,d
Diet + orlistat 0.4 ± 0.3 1.0 ± 0.3c 3.4 ± 1.1a,c,d 2.1 ± 0.7a,c,d
Magnesium mg/24 hours
Baseline 1.9 ± 1.0 2.6 ± 0.9 1.9 ± 0.5 2.1 ± 0.4
Diet 2.2 ± 0.2 1.4 ± 0.3a,c 0.7 ± 0.3a,c,d 0.7 ± 0.3a,c,d
Diet + orlistat 1.5 ± 0.4 1.6 ± 0.6a 0.5 ± 0.2a,c,d 1.0 ± 0.3a,c,d
Potassium mEq/L
Baseline 1.0 ± 0.2 1.1 ± 0.3 0.9 ± 0.4 0.8 ± 0.1
Diet 0.9 ± 0.2 2.0 ± 0.2a,c 1.5 ± 0.8a,c 1.7 ± 0.9a,c
Diet + orlistat 1.2 ± 0.8 2.4 ± 0.4a,c 2.1 ± 0.8a,c 2.8 ± 0.5a,b,c,d,e
Creatinine mg/24 hours
Baseline 6.2 ± 1.4 8.3 ± 1.0c 7.6 ± 3.2c 8.0 ± 1.9c
Diet 8.9 ± 2.5a 11.0 ± 2.0a,c,e 5.1 ± 2.3 8.9 ± 3.6e
Diet + orlistat 9.9 ± 3.5a 10.5 ± 0.9a,c 5.8 ± 1.2 7.2 ± 1.9d,e
pH
Baseline 6.9 ± 0.3 6.3 ± 0.3 6.7 ± 0.1 6.6 ± 0.2
Diet 6.8 ± 0.4 6.6 ± 0.4 7.0 ± 0.8 6.5 ± 0.8
Diet + orlistat 6.7 ± 0.4 6.5 ± 0.4 6.9 ± 0.3 6.5 ± 0.4
Data are presented as mean ± SD.
Comparison between periods. aP < 0.05 vs. baseline; b vs. diet.
Comparison between groups: different from (P < 0.05): c vs. Control; d vs. Soy Oil; e vs. NaOx.
results are presented as mean ± SD and the level of sig-
nificance was defined as P < 0.05.
RESULTS
Fecal fat and body weight
At baseline, the fecal fat was undetectable in all groups
and continued to be so in both control and NaOx groups
in diet and diet + orlistat periods. After orlistat use fecal
fat was increased to markedly high levels compared both
to the diet or baseline periods in soy oil group (22.7 ±
9.4% vs. 7.6 ± 1.3% vs. 0) and also in NaOx + soy oil
group (35.1 ± 11.4% vs. 9.8 ± 3.1% vs. 0), respectively.
As the gavaging of fat could have influenced the degree
of fat malabsorption due to a high amount of fat given
all at once, we performed an additional experiment in
ten rats that received orlistat plus fat mixed with the diet,
rather than gavaged, during 4 weeks, including the collec-
tion day. As the mean steatocrit in this group was 26%, a
similar result compared to that obtained in the main pro-
tocol, we considered that fat malabsorption occurred ir-
respective of the form of fat supplementation and did not
perform additional urinary determinations in this group.
After diet + orlistat period all groups presented a sig-
nificant mean weight gain compared both to diet or base-
line periods. Weight gain had been greater in the groups
that had received soy oil in the diet, despite of the pres-
ence of fat malabsorption (soy oil 340 ± 16 g vs. 328 ± 15 g
vs. 253 ± 87 g; NaOx + soy oil 360 ± 30 g vs. 339 ± 23 g
vs. 271 ± 21 g).
Urinary parameters
Table 1 shows the mean values of urinary volume, uOx,
uCa, uMg, uCit, uNa, uK, uCreat, and upH at baseline
and after the diet and diet + orlistat periods. After diet +
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Fig. 1. Mean ion-activity product of calcium oxalate [AP (CaOx) in-
dexrat] in baseline (), diet period ( ), and diet+orlistat period (). P <
0.05. ∗Different from baseline; #Different from diet period; aDifferent
from controls.
orlistat period, the mean urinary volume was significantly
lower in all groups except for controls, compared to
baseline. Baseline mean urinary volume was significantly
higher in soy oil vs. all other groups. The NaOx, soy oil,
and NaOx + soy oil groups presented a significantly lower
mean urinary volume compared to the control group after
orlistat use.
After the diet + orlistat period, the mean uOx excre-
tion was higher in all groups compared to baseline. In the
NaOx group, the increase was significantly different com-
pared to the diet period as well. Baseline mean values of
uOx did not differ between groups. Comparing the values
of uOx excretion between groups after diet + orlistat pe-
riod, mean uOx was markedly and significantly higher in
theNaOx + soy oil group vs. NaOx vs. soy oil vs. controls.
A significant decrease in mean uCa was observed in
all groups except for controls after the diet + orlistat pe-
riod compared to baseline. Baseline mean uCa was signif-
icantly lower in controls vs. all other groups. After the diet
+ orlistat period, the NaOx and NaOx + soy oil groups
presented a significantly lower mean uCa compared to
the controls and soy oil group.
A significant decrease in mean uCit after orlistat use
compared to baseline was only observed in the NaOx
group. Baseline uCit did not differ between groups. After
the diet + orlistat, a significantly lower mean uCit was
observed in all groups compared to controls.
With respect to mean uNa, after the diet + orlistat
an increase was observed in both groups that received
NaOx in the diet (NaOx and NaOx + soy oil), compared
to the baseline period. Baseline mean uNa did not differ
between groups. Mean uNa was significantly higher in the
NaOx and NaOx + soy oil groups than in the controls and
soy oil group, and significantly higher in thesoy oil group
than in the control group after the diet + orlistat period.
There was a significant decrease in mean uMg in all
groups but not in controls, after the diet + orlistat period
compared to baseline. Baseline mean uMg did not differ
between groups, but after the diet + orlistat there was
a significant reduction in uMg in groups that received
NaOx in the diet compared to the controls and soy oil
group.
A significant increase in mean uK excretion after the
diet + orlistat period was observed in all groups except for
controls, compared to baseline. Baseline uK did not differ
between groups. All three groups differed from controls
after the diet + orlistat period. The NaOx + soy oil group
presented a higher mean uK compared not only to con-
trols but also to the NaOx and soy oil groups.
Mean uCreat excretion was significantly higher in the
soy oil and control groups after the diet + orlistat pe-
riod versus baseline. Baseline mean uCreat was higher in
all groups vs. controls. After the diet + orlistat, a higher
mean uCreat concentration was observed in the soy oil
and NaOx + soy oil groups compared to the NaOx group,
with the soy oil group value being also significantly higher
compared to the NaOx + soy oil group.
There were no differences in mean upH between any
periods of the study or between groups.
AP (CaOx) indexrat
After the diet + orlistat, a significant increase in mean
AP (CaOx) indexrat was observed in the NaOx group
compared both to baseline and to the diet period, and
also in the NaOx + soy oil group compared both to base-
line and to the diet period (Fig. 1). Baseline mean AP
(CaOx) indexrat did not differ between groups. A higher
AP (CaOx) indexrat value was observed in all groups com-
pared to controls after the diet + orlistat period, except
for the soy oil group, in which the increase was only sig-
nificant after the diet period.
Histologic analysis
No CaOx crystal deposition or stones were detected in
the renal tissues under polarized light microscopy in any
of the groups.
DISCUSSION
Intestinal hyperabsorption of oxalate caused solely by
high oxalate intake is controversial [5, 42–44] but the im-
balance between intraluminal calcium and oxalate caused
by a low-calcium diet, absorptive hypercalciuria, or en-
teric hyperoxaluria is incontrovertible [10, 13, 45].
In enteric hyperoxaluria, malabsorbed fat reacts with
calcium reducing the formation of CaOx-insoluble com-
pounds in the intestinal lumen, hence raising free oxalate
absorption [14–17]. Several authors have reported that
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increasing dietary fat also leads to increased bile salt syn-
thesis in rats [46–48]. The present study aimed to deter-
mine whether the use of gastrointestinal lipase inhibitors
would induce fat malabsorption, and a surfeit of bile salts
with calcium-chelating properties, leading to a secondary
hyperabsorption of oxalate.
Our results showed that the use of lipase inhibitors
combined with a diet rich in oxalate associated or not
with fat leads to an increase in uOx excretion.
Orlistat has been administrated during 4 weeks [29,
49, 50] because our main purpose was to examine the
effects of the drug, commonly taken on a long-term basis,
upon oxalate excretion, urinary crystallization, and risk
of stone formation.
Since the use of gastrointestinal lipase inhibitors in our
animal model would not cause fat malabsorption, per se,
soy oil was added to the diet for some groups so that 35%
of the energy would derive from fat [30, 50]. In order to
increase the amount of oxalate available for absorption
and subsequent excretion, oxalate was further supple-
mented in some groups, in amounts already described in
the literature [43].
To ensure that fat malabsorption did occur, we mea-
sured fecal fat by the steatocrit technique, that despite
of not being the gold-standard method [51] is much eas-
ier to perform and commonly utilized in human studies
[34–37]. However, we are aware that the method is sub-
jective [34], not standardized in rats and should be rather
considered a qualitative than quantitative method.
With increasing dietary fat, as evidenced in the groups
that received soy oil, there was an increase in fecal fat
excretion, which was further enhanced by the use of li-
pase inhibitor. The higher fecal fat observed in NaOx +
soy oil group after the diet + orlistat period remained un-
explained but it might have been ascribed to the highly
variable reduction of fat absorption induced by orlistat
in rodents, ranging from 20% to 80% [49].
In clinical studies, many investigators have suggested
that dietary fat is directly correlated with oxalate ex-
cretion [52–54]. In the present experiment, the oil sup-
plement lead to a significant increase in uOx excretion.
However, the use of lipase inhibitors did not induce a
further increase in oxaluria, provided that dietary ox-
alate was not being concomitantly offered in the diet.
Thus, when only oxalate was supplemented, it produced
a threefold significant increase in uOx, similar to the find-
ings of Bushinski et al [43] who observed values of uOx
twice higher in hypercalciuric rats after oxalate loading
for 6 weeks. We observed that the use of orlistat induced a
further increase in oxaluria of almost fourfold compared
to baseline, even in the absence of fat. This elevation in
uOx was also significantly higher in comparison to the
period of diet alone. When both oxalate and oil supple-
ments were given, the increment in oxaluria reached six
times the baseline value, characterizing an additive effect
due to the concomitant presence of fat and excessive bile
salts in the intestinal lumen reacting with calcium and also
increasing colonic permeability to oxalate which further
enhanced free oxalate hyperabsorption. Finally, with the
addition of orlistat, uOx levels became eightfold higher
than at baseline.
Concerning calcium excretion, we observed that as di-
etary oil was increased, a fall in uCa took place, probably
due to binding with calcium, regardless of the use of orli-
stat. The supplementation of oxalate alone or associated
with orlistat use was accompanied by a fivefold fall in
uCa secondary to oxalate binding and the formation of an
unabsorbable solid phase of CaOx, confirming the pres-
ence of an inverse relationship between colonic oxalate
and calcium as previously suggested by several investi-
gators [4, 10, 11, 13, 42, 55, 56]. Orlistat did not further
reduce urinary calcium when both fat and oxalate were
supplemented.
We observed that increasing dietary oxalate also
caused a threefold reduction in uMg. Such reduction was
higher than the one found by da Silva et al [57], who em-
ployed lower amounts of oxalate. This can be explained
by the complexation of oxalate with magnesium in the in-
testinal lumen limiting the amount of free magnesium for
intestinal absorption, hence leading to lower magnesium
excretion [57–59]. We also noticed that the oil supple-
mentation alone reduced uMg possibly due to magnesium
binding with fat and bile salts in the intestinal lumen form-
ing soaps and decreasing absorption [60]. Orlistat did not
further decrease uMg.
There was a trend, albeit not significant, to a reduction
of uCit in all groups receiving either NaOx- or NaOx +
soy oil-supplemented diets. This lower uCit seemed to
parallel the decreases on uMg. According to McConnel
et al [17], the lower the availability of magnesium in the
renal tubule to bind citrate with, the higher the amount
of citrate left for reabsorption resulting in lowered uCit
levels.
As expected, uNa increased in the groups that received
a NaOx supplement. This increase in uNa should have
increased uCa as well [61, 62] but, as reported, uCa fell
in the oxalate-loaded rats, indicating that the effect of
oxalate on intestinal calcium binding was stronger than
the calciuric effect of sodium. Increases in uK excretion
paralleled the increases in uNa, probably resulting from
the higher delivery of sodium to the distal and collecting
tubules that act as a stimulus for potassium secretion at
these sites [63].
In our model of normal rats, no crystals or stones were
detected in any group, probably because CaOx urolithi-
asis is not a spontaneous phenomenon in rats [2], even
when uOx is increased. It has been extensively shown by
the group of Bushinsky et al [43, 64, 65] that the formation
of CaOx stones in hypercalciuric rats was only possible
when hydroxyproline or ammonium chloride was added
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to the diet. However, in the present experimental setting,
it was important to determine levels of supersaturation in
urine in order to assess if the resulting changes in urinary
parameters would represent a risk for stone formation.
Simplified estimates of the ion activity product of CaOx,
AP (CaOx) index, have been previously developed for
human urine [38] and present a good correlation with the
classical Equil 2 program [40]. A derivation of this index
has been recently adapted to rat urine by Tiselius, Ferraz,
and Heilberg [41]. This estimated AP (CaOx) indexrat,
based on the results of uOx, uCa, uMg, uCit, and volume,
helped us to address whether or not the use of gastroin-
testinal lipase inhibitors would interfere with the urinary
crystallization risk.
Orlistat induced a tremendous and significant increase
in AP (CaOx) indexrat in the groups that received ei-
ther oxalate or fat plus oxalate in the diet. The increase
in CaOx supersaturation was three times higher in the
NaOx group and 3.5 times higher in the NaOx + soy oil
group than that produced by the diet. A significant de-
crease in urinary volume and a similar reduction in citrate
and magnesium after orlistat observed in all groups could
have contributed to the increase in AP (CaOx) indexrat
per se. However, the marked and unique increase in uOx
observed mostly in NaOx+ soy oil group might have been
the main factor responsible for such a high AP (CaOx)
indexrat in this group, even considering the fall in uCa.
CONCLUSION
These data suggest that the use of lipase inhibitors, es-
pecially under a diet rich in oxalate associated or not with
fat, leads to a significant and marked increase in uOx and
a slight reduction in uCa and uMg that, taken together,
resulted in an increase in AP (CaOx) indexrat, elevating
the risk of stone formation.
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